<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130039</url>
  </required_header>
  <id_info>
    <org_study_id>TOSS-2</org_study_id>
    <nct_id>NCT00130039</nct_id>
  </id_info>
  <brief_title>Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II</brief_title>
  <acronym>TOSS-2</acronym>
  <official_title>Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Otsuka International Asia Arab</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will recruit 480 acute stroke patients with symptomatic intracranial stenosis (M1
      segment of Middle cerebral artery (MCA) or basilar artery).

      They will be randomly assigned into cilostazol group or clopidogrel group. Every patients
      will take 100mg of aspirin a day additionally.

      The primary outcome variable of this study is Progression rate of symptomatic intracranial
      stenosis on magnetic resonance angiogram (MRA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Goal] To Reveal the Effect and Safety of Cilostazol Compared with Clopidogrel on the
      Prevention of the Progression of Symptomatic Intracranial Arterial Stenosis.

      [Trial Design] Double-Blind, Active-Controlled, Randomized, Multicenter Trial

      [Participants] Acute ischemic stroke patients with symptomatic intracranial arterial stenosis

      [Methods]

        -  Double-Blind, Active-Controlled, Randomized, Multicenter Trial

        -  Investigational product (Double Dummy Method):

      Cilostazol 200mg (100mg twice per day) versus clopidogrel 75mg

        -  Concomitant medication: Aspirin 100 (75-150) mg per day

        -  Medication Duration: 7 months

      [Outcome Variables]

      Primary Outcome Variable:

        -  Progression rate of symptomatic intracranial arterial stenosis

      Secondary outcome variables:

        -  The occurrence of new MRI (magnetic resonance image) lesion on follow-up MRI

        -  Stroke events

        -  Overall cardiovascular events: stroke, acute coronary syndrome, vascular death

        -  Ipsilateral ischemic stroke rate

        -  Fatal or major bleeding complications
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Progression of Symptomatic Intracranial Stenosis</measure>
    <time_frame>7 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI</measure>
    <time_frame>7 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stroke Events</measure>
    <time_frame>upto 7 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Cardiovascular Events</measure>
    <time_frame>upto 7 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Ipsilateral Ischemic Stroke Rate</measure>
    <time_frame>upto 7 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Fatal or Major Bleeding Complications</measure>
    <time_frame>upto 7 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">457</enrollment>
  <condition>Cerebral Infarction</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol 100mg bid plus placebo of clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel 75mg qd and matching placebo of cilostazol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Clopidogrel 75mg once a day plus placebo of cilostazol twice a day</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix, produced by Sanofi-Aventis.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Cilostazol 100mg twice a day plus placebo of clopidogrel once a day</description>
    <arm_group_label>cilostazol</arm_group_label>
    <other_name>cilostazol produced by Korea Otsuka Pharmaceutical</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cerebral infarction within 2 weeks from the onset or TIA with corresponding acute
             ischemic brain lesions on MRI within 2 weeks from the onset

          -  Age: more than 35 years of age

          -  Patient with significant focal stenosis in the M1 segment of middle cerebral artery
             (MCA) or basilar artery (BA) with acute ischemic lesions on magnetic resonance imaging
             (MRI) within the vascular territory of the stenosed artery.

        Exclusion Criteria:

          -  Patients with any contraindications to the treatment with antiplatelet therapy

          -  Patients with potential cardiac embolic source; prosthetic valve, atrial fibrillation,
             atrial flutter, left atrial/atrial appendage thrombus, sick sinus syndrome, left
             ventricular thrombus, dilated cardiomyopathy, akinetic or hypokinetic left ventricular
             segment, atrial myxoma, Infective endocarditis, mitral valve stenosis or prolapse,
             mitral annuls calcification, left atrial turbulence, nonbacterial endocarditis,
             congestive heart failure, recent myocardial infarction (within 4 weeks)

          -  Patients with more than 50% stenosis in the parent artery of symptomatic stenosis

          -  Bleeding diathesis

          -  Chronic liver disease (ALT &gt; 100 or AST &gt; 100) or chronic renal disease (creatinine &gt;
             3.0mg/dl)

          -  Anemia (hemoglobin &lt; 10mg/dl) or thrombocytopenia (platelet count less than
             100,000/mm3)

          -  Nonatherosclerotic vasculopathy; patients with clinical characteristics suggesting
             arterial dissection, moyamoya disease, Takayasu's arteritis, radiation associated
             angiopathy, and other vasculitis.

          -  Severe stroke: NIH stroke scale : more than 16

          -  Pregnant or lactating patients

          -  Chronic user of NSAIDs

          -  Thrombolytic therapy for the symptomatic stenosis

          -  Symptomatic stenosis scheduled for angioplasty

          -  Patients with pacemaker or any other contraindications to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun U. Kwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center, Univsersity of Ulsan, Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk Univ. Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gwangjin-gu Hwayang-dong</state>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-do</state>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University International Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Kyoungki-do</state>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Kyunggi</state>
        <zip>430-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Inchon</city>
        <zip>400-103</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital, Hallym University</name>
      <address>
        <city>Seoul</city>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>140-743</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>280-1</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Santo Tomas Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2005</study_first_submitted>
  <study_first_submitted_qc>August 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <results_first_submitted>October 23, 2009</results_first_submitted>
  <results_first_submitted_qc>November 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2010</results_first_posted>
  <last_update_submitted>January 4, 2010</last_update_submitted>
  <last_update_submitted_qc>January 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sun U. Kwon</name_title>
    <organization>Asan Medical Center</organization>
  </responsible_party>
  <keyword>Infarction, Cerebral</keyword>
  <keyword>cilostazol</keyword>
  <keyword>stenosis</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>507 patients were registered www.toss2.com from 20 centers of 4 countries (Korea, Hongkong, Thailand, Philippines). 50 patients were excluded during case verification process because they did not satisfy patient's eligibility criteria.
finally 457 patients were randomized into cilostazol or clopidogrel group</recruitment_details>
      <pre_assignment_details>The excluded patients did not satisfy the definition of the symptomatic stenosis of our study protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cilostazol</title>
          <description>cilostazol 100mg twice a day plus placebo of clopidogrel</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel</title>
          <description>clopidogrel 75mg per day and matching placebo of cilostazol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202">full analysis set</participants>
                <participants group_id="P2" count="207">full analysis set</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>clinical events without follow up MRI</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cilostazol</title>
          <description>cilostazol 100mg twice a day plus placebo of clopidogrel</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel</title>
          <description>clopidogrel 75mg per day and matching placebo of cilostazol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="232"/>
            <count group_id="B2" value="225"/>
            <count group_id="B3" value="457"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.42" spread="11.33"/>
                    <measurement group_id="B2" value="64.58" spread="11.11"/>
                    <measurement group_id="B3" value="65.52" spread="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Progression of Symptomatic Intracranial Stenosis</title>
        <description>Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.
The progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA.</description>
        <time_frame>7 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol 100mg twice a day plus placebo of clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>clopidogrel 75mg per day and matching placebo of cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression of Symptomatic Intracranial Stenosis</title>
          <description>Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.
The progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI</title>
        <description>number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI.</description>
        <time_frame>7 months after treatment</time_frame>
        <population>this analysis included the patients who had performed follow-up FLAIR imaging</population>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol 100mg twice a day plus placebo of clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>clopidogrel 75mg per day and matching placebo of cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI</title>
          <description>number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI.</description>
          <population>this analysis included the patients who had performed follow-up FLAIR imaging</population>
          <units>pariticipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stroke Events</title>
        <description>including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke</description>
        <time_frame>upto 7 months after randomization</time_frame>
        <population>this outcome analysis performed on the intention to treat (ITT) method</population>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol 100mg twice a day plus placebo of clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>clopidogrel 75mg per day and matching placebo of cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stroke Events</title>
          <description>including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke</description>
          <population>this outcome analysis performed on the intention to treat (ITT) method</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Cardiovascular Events</title>
        <description>including nonfatal stroke, nonfatal myocardial infarction and vascular death.</description>
        <time_frame>upto 7 months after randomization</time_frame>
        <population>this outcome analysis was done intention to treat method</population>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol 100mg twice a day plus placebo of clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>clopidogrel 75mg per day and matching placebo of cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Cardiovascular Events</title>
          <description>including nonfatal stroke, nonfatal myocardial infarction and vascular death.</description>
          <population>this outcome analysis was done intention to treat method</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Ipsilateral Ischemic Stroke Rate</title>
        <description>ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis</description>
        <time_frame>upto 7 months after randomization</time_frame>
        <population>this outcome analysis was done ITT method</population>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol 100mg twice a day plus placebo of clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>clopidogrel 75mg per day and matching placebo of cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Ipsilateral Ischemic Stroke Rate</title>
          <description>ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis</description>
          <population>this outcome analysis was done ITT method</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers of Fatal or Major Bleeding Complications</title>
        <description>life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood</description>
        <time_frame>upto 7 months after randomization</time_frame>
        <population>this outcome analysis was done ITT method</population>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol 100mg twice a day plus placebo of clopidogrel</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>clopidogrel 75mg per day and matching placebo of cilostazol</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Fatal or Major Bleeding Complications</title>
          <description>life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood</description>
          <population>this outcome analysis was done ITT method</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cilostazol</title>
          <description>cilostazol 100mg twice a day plus placebo of clopidogrel</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel</title>
          <description>clopidogrel 75mg per day and matching placebo of cilostazol</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>severe hypertension</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>otitis media</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>vestibular neuronitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes complications</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>cataract operation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>'Blood tinged loose stool</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>GI bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>traffic accident</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>fracture or other joint pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>abnormal involuntary movement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>cerebral infarction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="232"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>cerebral hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>general weakness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>aneurysm unruptured</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>petechia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="232"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="232"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>epigastric soreness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="232"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>GI bleedings</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="78" subjects_affected="62" subjects_at_risk="232"/>
                <counts group_id="E2" events="42" subjects_affected="35" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="232"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>others</sub_title>
                <counts group_id="E1" events="565" subjects_affected="169" subjects_at_risk="232"/>
                <counts group_id="E2" events="564" subjects_affected="225" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sun U. Kwon, MD, PhD, Prof</name_or_title>
      <organization>Asan Medical Center, University of Ulsan</organization>
      <phone>82-2-3010-3960</phone>
      <email>sukwon@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

